Industry Expertise (2)
Areas of Expertise (5)
Nonivasive Drug & Gene Delivery
University of Texas at Austin: Postdoc, Chemistry & Biochemistry
University of Texas at Austin: Ph.D., Chemical Engineering
Federal University of Santa Catarina (Brazil): M.S., Chemical Engineering
Federal University of Santa Maria (Brazil): B.S., Chemical Engineering
- Frontiers in Colloidal Materials and Interfaces
- Journal of Pharmaceutics
- Advances in Pharmaceutics
- Chemical Engineering and Process Techniques
Media Appearances (1)
VCU launches Center for Pharmaceutical Engineering and Sciences
Virginia Business online
“The idea is to translate this new knowledge and discoveries into real products,” says Sandro R.P. da Rocha, a professor in the School of Pharmacy.
Selected Articles (3)
Poly(amidoamine) Dendrimer–Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose InhalersMolecular Pharmaceutics
2016 Lung cancers are the leading cause of cancer death for both men and women. A series of PEGylated poly(amidoamine) dendrimer-based doxorubicin (DOX) nanocarriers (G3NH2-mPEG-nDOX) were synthesized and their chemistry tailored for the development of novel pseudosolution formulations in propellant-based metered-dose inhalers (pMDIs) with enhanced aerosol characteristics.
Effect of the Conjugation Density of Triphenylphosphonium Cation on the Mitochondrial Targeting of Poly(amidoamine) DendrimersMolecular Pharmaceutics
2015 Many clinically relevant diseases with known poor therapeutic outcomes, including cancer and neurodegenerative disorders, have been directly linked to mitochondrial dysfunction. The ability to efficiently target therapeutics to intracellular organelles such as mitochondria may represent new opportunities for the effective treatment of such ailments.
Poly(amidoamine) Dendrimer Nanocarriers and Their Aerosol Formulations for siRNA Delivery to the Lung EpitheliumMolecular Pharmaceutics
2014 Small interfering RNA (siRNA)-based therapies have great promise in the treatment of a number of prevalent pulmonary disorders including lung cancer, asthma and cystic fibrosis. However, progress in this area has been hindered due to the lack of carriers that can efficiently deliver siRNA to lung epithelial cells, and also due to challenges in developing oral inhalation (OI) formulations for the regional administration of siRNA and their carriers to the lungs.